Francisco Domínguez C

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

Background: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. Aim: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. Patients and Methods: We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen(ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. Results: We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). Conclusions: Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.BACKGROUND The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. AIM To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. PATIENTS AND METHODS We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. RESULTS We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). CONCLUSIONS Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.

Rendimiento de la biopsia intraoperatoria por congelación en el estudio del linfonodo centinela en cáncer de mama

Introduccion: La biopsia del linfonodo centinela (LC) se ha convertido en la tecnica estandar para estadificar el compromiso axilar en el cancer de mama. El diagnostico intraoperatorio del compromiso metas-tasico del linfonodo permite decidir en forma inmediata la necesidad de diseccion axilar. El objetivo general de este estudio fue determinar el rendimiento de la biopsia intraoperatoria por congelacion en la pesquisa de metastasis en el LC, en pacientes con cancer de mama, entre 1999 y 2011. Material y Metodos: Estudio retrospectivo de las pacientes operadas por cancer de mama invasor, en que se realizo biopsia del LC, con estudio intraoperatorio por congelacion. Resultados: 503 pacientes con biopsia del LC con estudio intrao-peratorio. Ciento cincuenta y cuatro (30,6%) pacientes tuvieron metastasis en el LC, de estos 103 (66,9%) fueron detectadas en la biopsia rapida. No hubo diferencias significativas en la capacidad de deteccion para los tumores de hasta 2 cm y los tumores mayores de 2 cm (p = 0,86). La sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo (VPN) de la biopsia intraoperatoria para la deteccion de metastasis en el LC fue de 66,9%, 99,7%, 99% y 87%, respectivamente. Conclusiones: El rendimiento obtenido es comparable al descrito en la literatura, siendo efectiva solo para la pesquisa de macrometastasis (MA). Dada la baja frecuencia de metastasis en el LC en tumores de hasta 2 cm, asociado a un numero relativamente alto de micro (MI) y submicrometastasis (SM) y de falsos negativos, nos parece que, en estos casos, la utilizacion de la biopsia intraoperatoria del LC es innecesaria.

IMPACTO DE LAS METÁSTASIS DEL LINFONODO CENTINELA Y SU TAMAÑO, EN EL TRATAMIENTO DEL CÁNCER DE MAMA

Impact of sentinel lymph node metastases in the treatment of breast cancer Introduction: The importance of sentinel lymph nodes (SL) metastasis at breast cancer patients has been questioned and observation without axillary dissection (AD) associated with adjuvant therapies has been the recommendation in recent years. Objective: To evaluate the macro (MA), micro (MI) and submicrome- tastasis (SM) of breast cancer in SL, and their impact on the posterior AD. Methods: We reviewed results of biopsies from patients with invasive breast cancer with MA, MI and SM found in the SL operated at our institution between May 1999 and December 2011. Results: We found 134 patients with MA, 33 patients with MI and 30 patients with SM, in a total of 632 patients with invasive breast cancer in those who underwent SL. These were operated 130, 24 and 17 patients respectively. The frequency of no sentinels lymph nodes (NSL) with metastases found on AD was 46.9% (61/130) for MA, 33.3% (8/24) for MI and 23.5% (4/17) for SM. The NSL metastasis from MA modified the TNM in 26.9% (35/130), those from MI in 20.8% (5/24) patients, while the SM only modified in one patient (5.9%). Conclusions: The frequency of lymph nodal involvement in AD is significantly higher in patients with MA. The number of AD without clear therapeutic input is high and increases with decreasing size of SL metastases. The results support to not perform AD in patients with MI and SM in the SL, who received conservative surgery and adjuvant therapy.

Cáncer medular de tiroides: Experiencia quirúrgica en 10 años

Background: Medullary thyroid cancer (MTC) represents approximately 5% of all thyroid cancers. Surgery is the only curative treatment, which includes total thyroidectomy and in most cases, neck dissection. Aim: To report our 10-year experience with surgical treatment of MTC. Material and methods: Review of medical records and pathology reports of a university hospital. We retrieved data from 28 patients aged 47.2 ± 16 years (21 women) operated for a MTC treated between June 2002 and June 2012. Results: In 20 patients, MTC was diagnosed in the preoperative period. Total thyroidectomy was performed in all cases and included a neck dissection in 24 patients. Median follow-up was 48 (2-120) months. Twenty-five patients (89.2%) achieved complete remission of the disease and three had disease recurrence. There were no deaths during the follow up. Conclusions: The diagnosis of MTC is mainly based on cytology. Total thyroidectomy with neck dissection is the treatment of choice. An early-stage diagnosis is associated with low rates of recurrence and absence of mortality.

NUEVAS TERAPIAS SISTÉMICAS PARA EL TRATAMIENTO DEL MELANOMA

Resumen El melanoma es un tumor maligno que tiene una alta tendencia a metastizar localmente, regionalmente al sistema linfatico, y en forma sistemica, preferentemente a pulmones, higado, cerebro y hueso. La cirugia es el principal tratamiento para el melanoma, con excelentes resultados en estadios precoces, pero escasa utilidad en etapas avanzadas con enfermedad sistemica. Tradicionalmente los tratamientos en base a quimioterapias citotoxicas han aportado poco beneficio a los pacientes en etapa IV, lo que ha motivado una amplia investigacion e innovacion en esta area. Actualmente la Food and Drug Administration (FDA) ha aprobado nuevas terapias para el tratamiento del melanoma metastasico, irresecable o recurrente, en base a drogas inmuno moduladoras y drogas que bloquean la transduccion de senales, con resultados muy promisorios. Los cirujanos que tratamos pacientes con melanoma, debemos estar al dia sobre el uso de estas nuevas terapias que representan una nueva oportunidad de tratamiento para nuestros pacientes.

CUÁNDO Y CÓMO REALIZAR UNA BIOPSIA DE LAS LESIONES CUTÁNEAS FRECUENTES: LO QUE EL CIRUJANO DEBE SABER

En la actualidad, el cirujano continuamente se ve enfrentado a evaluar distintos tipos de lesiones cutaneas en los pacientes, por lo que debe tener conocimientos de las caracteristicas que hacen que una lesion sea sospechosa o no, para evaluar correctamente cuando y como realizar una biopsia de una lesion cutanea. El diagnostico precoz, tanto del melanoma como del cancer de piel no melanoma, ha demostrado ser clave para mejorar el pronostico de nuestros pacientes. Este articulo pretende entregar algunas claves para afinar la evaluacion y diagnostico de las lesiones pigmentadas. Es muy importante tambien, recalcar la importancia del trabajo conjunto de los cirujanos con los dermatologos, ya que la evaluacion y manejo multidisciplinario mejora sustancialmente el diagnostico, tratamiento y resultados de los pacientes con cancer de piel.

CARACTERÍSTICAS CLÍNICO-PATOLÓGICAS Y SOBREVIDA DE PACIENTES CON CÁNCER DE MAMA BILATERAL SINCRÓNICO

Clinicopathological features and survival of patients with bilateral synchronous breast cancer Introduction: Bilateral synchronous breast cancer (BSBC) has a variable incidence and conflicting data on prognosis. Our goal is to evaluate the characteristics and survival of patients with BSBC treated at Cancer Center of the Pontificia Universidad Catolica de Chile. Patients and Methods: Descriptive study. We identified patients treated between January 1999 and May 2013. We evaluated and compared characteristics from BSBC patients with a local cohort of non-synchronous breast cancer. Results: The incidence of BSBC was 1.8% (n = 28). Three patients were excluded because of missing data. Therefore we analyzed 25 patients (50 tumors). Median age: 50 years (33-84). The dominant tumors diagnosis was clinical in 47.6% of cases, and imaging in 90.5% of the contra-lateral non-dominant (p = 0.04). Average tumor size of invasive tumors was 2.5 cm for dominant tumor versus 1.7 cm for the non-dominant (p = 0.02). 81.4% of invasive tumors were estrogen receptor (ER) positive. Histological and subtype concordance between both tumors was 88% and 72% respectively. 54% of patients with BSBC were managed with total mastectomy versus 28.4% in the control group no BSBC (p = 0.0001). The estimated overall survival at 10 years was 76.5% in patients with no BSBC versus 62% in those with BSBC (p = 0.08). Conclusions: The BSBC is rare. Frequently they are ER positive tumors, mostly diagnosed through images and managed with less conservative surgery.

Carcinoma basoescamoso: Reporte de un caso con exposición crónica a arsénico ambiental

El carcinoma basoescamoso es una neoplasia cutanea relativamente rara que reune caracteristicas de carcinoma basocelular y espinocelular. Actualmente la mayoria de los dermatologos reconocen que este es un subtipo del carcinoma basocelular con comportamiento muchisimo mas agresivo. Su presentacion clinica es inespecifica y en general su diagnostico se realiza solo despues de la biopsia. Predomina en pacientes de sexo masculino durante la septima decada de la vida y tiende a aparecer en regiones fotoexpuestas. Muchos autores igualan su comportamiento al del carcinoma espinocelular. Se presenta el caso de un paciente, de sexo masculino, de 44 anos de edad, con antecedente de exposicion a arsenico medioambiental cronica, que presento aumento de volumen, duro en la region inguinal izquierda, cuya biopsia fue compatible con carcinoma basoescamoso con compromiso linfatico. El caso de nuestro paciente muestra una presentacion atipica por su localizacion y por la aparicion 20 anos antes de la media de edad reportada en la literatura. Esto podria ser explicado por la exposicion cronica a arsenico, conocido factor de riesgo para carcinogenesis cutanea.